Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2020-12-20
Target enrollment:
Participant gender:
Summary
After the second-line treatment of patients with non-T790M mutations, chemotherapy with
platinum-containing drugs was used, and chemotherapy-related toxicity was high. Studies have
shown that bevacizumab combined with EGFR TKI have a good trend of benefit. This study is
aimed to evaluate the efficacy and safety of Anlotinib Hydrochloride combined with
first-generation EGFR TKIs as second-line treatment in advanced non-small cell lung cancer .
The patients with IV non-small lung cancer have acquired resistance to prior first-generation
EGFR TKIs and have non-T790M mutation.
Phase:
N/A
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Collaborators:
Affiliated Hospital of Jiangnan University Changzhou No.2 People's Hospital Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd Jiangyin People's Hospital Nantong University Second Affiliated Hospital of Soochow University The First People's Hospital of Changzhou